Status: Not yet recruiting
Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
This study aims to study the efficacy and safety of oral cyclophosphamide in addition to carfilzomib and dexamethadone for RRMM patients who have been previously exposed to lenalidomide combination therapies.
Participants needed: 49
Trial details
Phase: Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: Dong-A University HospitalUpdated: Jun 18, 2023
Eligibility criteria
Subjects aged 19 years or older [+22]
Myocardial infarction within 6 months prior to treatment, New York Heart Associa... [+4]